Pfizer Inc. (NYSE:PFE) said the U.S. Food and Drug Administration has approved its oncology biosimilar Zirabev for the treatment of five types of cancer. The FDA has approved the drug to treat metastatic colorectal cancer, unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, and persistent, recurrent or metastatic cervical cancer, Pfizer said in a statement. Biosimilars are cheaper versions of complex medicines.
Pfizer Inc. (NYSE:PFE), a Healthcare sector firm, traded 20.79 Million shares in last trading session with closing price of $43.43 per share. Company gross margin stands at 79.60% whereas its return on investment (ROI) is 10.20%. Stock value has moved between $35.89 – 46.7 in last one year. Analyst’s mean target price for Pfizer Inc. (NYSE:PFE) is $45.57 while analysts mean recommendation is 2.40. PFE EPS growth this year is -11.90%.
On last trading day, BB&T Corporation (NYSE:BBT) shares closed at $48.18 per share. BBT market capitalization is 36962.73 with beta of 1.11. Analyst’s mean target price for BB&T Corporation (NYSE:BBT) is $55.47 whereas analysts mean recommendation is 2.40. Its weekly performance is -1.09% while year to date (YTD) performance is 11.22%.
In last session Wells Fargo & Company (NYSE:WFC) traded 13.24 Million shares and was closed at $46.29. Analyst’s mean target price for WFC is $52.00 while analysts mean recommendation is 2.70. Company is -22.23% away from its 52 week high and is moving 7.60% ahead of its 52 week low. WFC return on assets is 1.10%. Wells Fargo & Company (NYSE:WFC) quarterly performance is -5.70% while its price to sale ratio is 3.18.
VEREIT, Inc. (NYSE:VER), a Financial sector firm, traded 9.46 Million shares on last trading day with closing price of $8.89 per share. Company gross margin stands at 89.80% whereas its return on investment (ROI) is 0.60%. Stock value has moved between $6.89 – 9.66 in last one year. Analyst’s mean target price for VEREIT, Inc. (NYSE:VER) is $8.78 while analysts mean recommendation is 2.70. VER EPS growth this year is -656.40%.
